<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03885895</url>
  </required_header>
  <id_info>
    <org_study_id>EgyFreckles</org_study_id>
    <nct_id>NCT03885895</nct_id>
  </id_info>
  <brief_title>Treatment of Freckles by Intradermal Tranexamic Acid Versus Q Switched KTP Laser.</brief_title>
  <official_title>Comparative Study for the Treatment of Freckles by Intradermal Tranexamic Acid Versus Q Switched KTP Laser (532nm)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kasr El Aini Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kasr El Aini Hospital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Comparative split face study in which 30 patients with freckles are recruited.One side of the
      face will be treated with Q Switched (QS)KTP 532nm, and the other side will be treated with
      intradermal tranexamic acid (TXA).
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      One side of the face will receive QS KTPlaser at a wavelength of 532 nm, spot size 2-3 mm ,
      power 1-1.5J/cm2 and the clinical end point is just frosting.Sessions will be every month for
      2 months.

      The other side of the face will be assigned to TXA intradermal microinjection in the same
      session using Kapron 500mg/5ml ampoules (Amoun Pharmaceutical Company), the dose of 1 ml
      syringe with 100mg/ml. TXA will prepared under sterile conditions. Injections will be applied
      intradermally on freckles area at.

      The sessions of TXA will be every 2 weeks for 2 months.

      Postoperatively, topical antibiotic ointment and steriod will be applied. Sunscreen then
      applied until the next treatment in order to minimize reactive hyperpigmentations.

      Follow up after treatment monthly for 2 month.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 15, 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">August 2019</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double (Participant, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pigmentation and severity index by clinical evaluation</measure>
    <time_frame>6 months to 1 year</time_frame>
    <description>Evaluate efficacy of intradermal tranexamic acid versus Q switched KTP laser in the treatment of freckles before treatment, after treatment and after follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Melanin Index change by spectrophotometer</measure>
    <time_frame>6 months to 1 year</time_frame>
    <description>Evaluate efficacy of intradermal tranexamic acid versus Q switched KTP laser in the treatment of freckles before treatment, after treatment and after follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Blinded observers' evaluation</measure>
    <time_frame>6 months to 1 year</time_frame>
    <description>Evaluate efficacy of intradermal tranexamic acid versus Q switched KTP laser in the treatment of freckles before treatment, after treatment and after follow-up</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Patient satisfaction rate</measure>
    <time_frame>6 months to 1 year</time_frame>
    <description>Evaluate efficacy of intradermal tranexamic acid versus Q switched KTP laser in the treatment of freckles before treatment, after treatment and after follow-up</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">30</enrollment>
  <condition>Therapeutic Efficacy</condition>
  <arm_group>
    <arm_group_label>Participants with freckles (one side of the face)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>one randomized side of the face will be treated by Intradermal Tranexamic acid</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Participants with freckles (other side of the face)</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>other side will be treated by Q switched KTP laser</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tranexamic Acid Injectable Product</intervention_name>
    <description>Ampoules used for intradermal injection</description>
    <arm_group_label>Participants with freckles (one side of the face)</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Q switched KTP (532nm)</intervention_name>
    <description>LASER</description>
    <arm_group_label>Participants with freckles (other side of the face)</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Both genders

          -  Age group &gt; 18years old.

        Exclusion Criteria:

          -  Pregnant and lactating females.

          -  Keloid and scarring tendancy

          -  Usage of invasive or semi invasive procedures for treatment of freckles such as
             chemical peeling , dermaroller..etc. 2 months prior to the study.

          -  Oral Isotretinoin 6 months prior to the study.

          -  Active herpetic lesions.

          -  Any concurrent active skin disease within the treated area.

          -  Photosensitive skin conditions such as systemic lupus erythematous.

          -  History of delayed wound healing.

          -  Bleeding diathesis.

          -  Medical conditions such as autoimmune diseases.
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Samar Tuqan</last_name>
    <phone>01003133495</phone>
    <phone_ext>02</phone_ext>
    <email>samartuqan@gmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Kasr El Ainy university hospital</name>
      <address>
        <city>Cairo</city>
        <zip>11956</zip>
        <country>Egypt</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samar Tuqan</last_name>
      <phone>01003133495</phone>
      <phone_ext>02</phone_ext>
      <email>samartuqan@gmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 20, 2019</study_first_submitted>
  <study_first_submitted_qc>March 20, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">March 22, 2019</study_first_posted>
  <last_update_submitted>March 20, 2019</last_update_submitted>
  <last_update_submitted_qc>March 20, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">March 22, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Kasr El Aini Hospital</investigator_affiliation>
    <investigator_full_name>Rana F Hilal, MD</investigator_full_name>
    <investigator_title>Lecturer</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Melanosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Tranexamic Acid</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

